がん悪液質(Cancer Cachexia):世界の治験レビュー(2016年上半期版)

【英語タイトル】Cancer Cachexia Global Clinical Trials Review, H1, 2016

GlobalDataが出版した調査資料(GDHC3223CTIDB)・商品コード:GDHC3223CTIDB
・発行会社(調査会社):GlobalData
・発行日:2016年2月
・ページ数:79
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界におけるがん悪液質(Cancer Cachexia) 治療の臨床試験動向について調査・分析し、アジア太平洋/欧州/北米/中南米の主要国における治験件数、段階(フェーズ)別の治験件数、進捗状況別の治験件数、治験目標の達成状況、有望な薬剤、治験関連の最新ニュース、代表的な企業・大学・研究機関における治験概要、代表的な治験のプロファイルなどのデータをまとめてお届けいたします。

・イントロダクション
  - がん悪液質(Cancer Cachexia)
  - 当レポートの概要
・がん悪液質(Cancer Cachexia):各地域別治験状況
  - 各国の治験件数及び平均被験者数
   アジア太平洋の主要国における治験件数
   欧州の主要国における治験件数
   北米の主要国における治験件数
   中東・アフリカの主要国における治験件数
   中南米の主要国における治験件数
・G7諸国での治験件数
・G7諸国での治験件数:段階別
・G7諸国での治験件数:進捗状況別
・段階(フェーズ)別の治験件数:進行中の治験(段階別)
・進捗状況別の治験件数
・治験目標の達成状況
・未完了の治験件数
・一定期間に採用された被験者
・スポンサーの種類別治験件数
・有望なスポンサー
・有望な薬剤
・治験のプロファイル
  - 代表的な企業における治験概要
  - 代表的な大学・研究機関における治験概要
・5つの代表的な治験のプロファイル
【レポートの概要】

Cancer Cachexia Global Clinical Trials Review, H1, 2016

Summary

GlobalData’s clinical trial report, “Cancer Cachexia Global Clinical Trials Review, H1, 2016″ provides an overview of Cancer Cachexia clinical trials scenario. This report provides top line data relating to the clinical trials on Cancer Cachexia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Cancer Cachexia to Musculoskeletal Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Cancer Cachexia to Musculoskeletal Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Cancer Cachexia Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 76
Abbreviations 76
Definitions 76
Research Methodology 77
Secondary Research 77
About GlobalData 78
Contact Us 78
Disclaimer 78
Source 79

List of Tables
Cancer Cachexia Therapeutics, Global, Clinical Trials by Region, 2016* 6
Cancer Cachexia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Cancer Cachexia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Cancer Cachexia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Cancer Cachexia Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Cancer Cachexia Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Cancer Cachexia Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Cancer Cachexia Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Cancer Cachexia to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 14
Cancer Cachexia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Cancer Cachexia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Cancer Cachexia to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 17
Cancer Cachexia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Cancer Cachexia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Cancer Cachexia Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Cancer Cachexia Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Cancer Cachexia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Cancer Cachexia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Cancer Cachexia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Cancer Cachexia Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Cancer Cachexia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Cancer Cachexia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Cancer Cachexia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Cancer Cachexia Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Cancer Cachexia Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Cancer Cachexia Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Cancer Cachexia Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Cancer Cachexia Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Cancer Cachexia Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Cancer Cachexia Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Proportion of Cancer Cachexia to Musculoskeletal Disorders Clinical Trials, G7 Countries (%), 2016* 14
Cancer Cachexia Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Cancer Cachexia Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Cancer Cachexia to Musculoskeletal Disorders Clinical Trials, E7 Countries (%), 2016* 17
Cancer Cachexia Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Cancer Cachexia Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Cancer Cachexia Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Cancer Cachexia Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Cancer Cachexia Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Cancer Cachexia Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Cancer Cachexia Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Cancer Cachexia Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Cancer Cachexia Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Cancer Cachexia Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Cancer Cachexia Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 77

【掲載企業】

GTx, Inc.
Helsinn Holding S.A.
Medpace, Inc.
Novartis AG
XBiotech USA, Inc.
Ono Pharmaceutical Co., Ltd.
Ohr Pharmaceutical Inc.
Merck & Co., Inc.
Ark Therapeutics Limited
Aeterna Zentaris Inc.

【レポートのキーワード】

がん悪液質(Cancer Cachexia)、治験、臨床試験、治験、治療薬

★調査レポート[がん悪液質(Cancer Cachexia):世界の治験レビュー(2016年上半期版)] (コード:GDHC3223CTIDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[がん悪液質(Cancer Cachexia):世界の治験レビュー(2016年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆